Hipotiroidismo central y dislipemia mixta secundarios a tratamiento con bexaroteno

Article information

El bexaroteno es un análogo de retinoide sintético caracterizado por unirse selectivamente a un tipo de receptores retinoides (receptores X) que fue diseñado para el tratamiento, entre otros, de estadios avanzados de linfoma cutáneo de células T resistentes a tratamientos convencionales. Se ha descrito que hasta el 40% de los pacientes que reciben bexaroteno pueden desarrollar hipotiroidismo secundario y hasta el 70%, hiperlipemia mixta grave, efecto común a otros retinoides. Presentamos a 3 pacientes que desarrollaron hipotiroidismo central y dislipemia tras el inicio de tratamiento con bexaroteno; en uno de ellos pudimos observar que estas alteraciones remitían tras la supresión del tratamiento.

Palabras clave:

Ligando selectivo del receptor X retinoico

Hipotiroidismo central

Bexaroteno

Bexarotene is a synthetic retinoid analogue that joints selectively to retinoid X receptor and has been designed for treatment of advanced stages of cutaneous T- cell lymphoma. Up to a 40% of patients treated with bexarotene develop central hypothyroidism while severe mixed dyslipidemia may be present in up to 70%. We report 3 patients that developed central hypothyroidism and dyslipidemia after bexarotene treatment was initiated. In one of them, we observed normalization of the thyroid function when bexarotene treatment was stopped.

Key words:

Retinoid X receptor-selective ligands

Central hypothyroidism

Bexarotene

Full text is only aviable in PDF

Bibliografía

[1.]

S. Liu, K.M. Ogilvie, K. Klausing, M.A. Lawson, D. Jolley, D. Li, et al.

Mechanism of selective retinoid X receptor agonist induced hypothyroidism in the rat.

Endocrinology, 143 (2002), pp. 2880-2885

http://dx.doi.org/10.1210/endo.143.8.8930 | Medline

[2.]

S.I. Sherman.

Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma.

Clin Lymphoma, 3 (2003), pp. 249-252

Medline

[3.]

S.I. Sherman, J. Gopal, B.R. Haugen, A.C. Chiu, K. Whaley, P. Nowlakha, et al.

Central hypothyroidism associated with retinoid X receptor-selective ligands.

N Engl J Med, 340 (1999), pp. 1075-1079

http://dx.doi.org/10.1056/NEJM199904083401404 | Medline

[4.]

N. Sucunza, M.P. García Muret, J. Rodríguez, R. Corcoy.

Hipotiroidismo secundario a tratamiento con bexatoteno.

Med Clin (Barc), 125 (2005), pp. 559

[5.]

W.C. Yen, R.Y. Prudente, M.R. Corpuz, A. Negro-Vilar, W.W. Lamph.

A selective retinoid X receptor agonist bexarotene (LGD-1069, targretin) inhibits angiogenesis and metastasis in solid tumours.

Br J Cancer, 94 (2006), pp. 654-660

http://dx.doi.org/10.1038/sj.bjc.6602995 | Medline

[6.]

C. Asteria.

Treatment with retinoid X receptor gamma-selective ligand (bexarotene) may cause iatrogenic central hypothyroidism.

Eur J Endocrinol, 142 (2000), pp. 324-325

Medline

[7.]

V.A. Miller, F.M. Benedetti, J.R. Rigas, A.L. Verret, D.G. Pfister, D. Straus, et al.

Initial clinical trial of a selective retinoid X receptor ligand LGD 1069.

J Clin Oncology, 15 (1997), pp. 790-795

[8.]

S.X. Cheng, T. Kupper.

A new rexinoid for cutaneous T cell lymphoma.

Arch Dermatolol, 137 (2001), pp. 649-652

[9.]

B. Staels.

Regulation of lipid and lipoprotein metabolism by retinoids.

J Am Acad Dermatol, 45 (2001), pp. S158-S167

http://dx.doi.org/10.1067/mjd.2001.113718 | Medline

[10.]

M. Duvic, A. Martin, Y. Kim, E. Olsen, G. Wood, C.A. Crowley, et al.

Phase 2 and 3 clinical trial of oral bexarotene (Tagretin Capsules) for the treatment of refractory or persistent earlystage cutaneous T-cell lymphoma.

Arch Dermatol, 137 (2001), pp. 581-593

Medline

[11.]

M. Duvic, K. Hymes, P. Heald, D. Breneman, A.G. Martin, P. Myskowski, et al.

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

J Clin Oncology, 19 (2001), pp. 2456-2471

Rosa Corcoy Plà está vinculada a la red de centros del Instituto de Salud Carlos III, RCMN C03/08.